8-K: Neumora Reports Positive NMRA-511 AD Agitation Data, Outlines 2026 Milestones

Neumora Therapeutics announced positive Phase 1b results for NMRA-511 in Alzheimer's disease agitation and detailed key pipeline updates and anticipated milestones for 2026.

Summary

• Positive results from the Phase 1b signal-seeking study of NMRA-511 in people with Alzheimer's disease (AD) agitation were announced.
• NMRA-511 demonstrated a 15.7% reduction on mean CMAI total score, indicating a clinically meaningful effect.
• In a pre-specified population with elevated anxiety, NMRA-511 showed an unsurpassed clinical effect size on CMAI total score, with a Cohens d effect size range of 0.51 – 0.64 at Weeks 6 and 8.
• The drug exhibited a favorable tolerability and safety profile, with no reports of somnolence or sedation.
• Neumora plans to advance NMRA-511 development, including initiating a multiple ascending dose extension study and formulation development for once-daily dosing in 2026, followed by a Phase 2/3 dose ranging study.
• The company provided 2026 pipeline strategy and anticipated milestones, including a joint topline data readout for KOASTAL-2 and KOASTAL-3 (navacaprant for MDD) in Q2 2026, with increased enrollment.
• Neumora expects to initiate a clinical program for NMRA-215 (obesity) in H1 2026 and report weight loss data around the end of 2026.
• Updates on the M4 Positive Allosteric Modulator (PAM) franchise (NMRA-898 and NMRA-861) are expected in mid-2026.
• Cash, cash equivalents, and marketable securities are projected to support operations into Q3 2027.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data for NMRA-511, addressing a high unmet medical need with a favorable safety profile. Combined with a robust pipeline of other programs advancing towards significant milestones in 2026 and a solid cash runway, the overall sentiment is highly positive, indicating strong operational progress and future potential.

Positives

• NMRA-511 achieved a clinically meaningful 15.7% reduction on mean CMAI total score in AD agitation.
• The drug demonstrated an unsurpassed clinical effect size (Cohens d 0.51 – 0.64) in AD agitation patients with elevated anxiety.
• NMRA-511 showed a favorable tolerability and safety profile with low treatment discontinuations (2.5%) due to adverse events and no somnolence or sedation.
• The company has a strong financial position, with cash, cash equivalents, and marketable securities expected to fund operations into Q3 2027.
• Advancement of multiple pipeline programs, including navacaprant, NMRA-215, and M4 PAMs, with several data readouts anticipated in 2026.
• NMRA-215 showed class-leading preclinical data for obesity.

Negatives

• The Phase 1b study for NMRA-511 was signal-seeking and not powered for statistical significance, meaning the clinical effects observed, while meaningful, are not yet statistically proven in this specific study design.
• Common adverse effects (>5%) were reported, including nasopharyngitis, urinary tract infection, anemia, arthralgia, diarrhea, dizziness, headache, hyponatremia, myalgia, nausea, vomiting, and abdominal pain.

Risks

• Inherent uncertainty of clinical drug development and the unpredictable, lengthy process for obtaining regulatory approvals.
• Risks related to the timely initiation and enrollment in clinical trials.
• Reliance on third parties, including contract research organizations.
• Potential for serious or undesirable side effects of therapeutic candidates.
• Risks related to the ability to utilize and protect intellectual property rights.
• Matters that could affect the sufficiency of capital resources to fund operations.
• Comparisons to efficacy results from other sponsors should be interpreted with caution due to differences in compounds, study designs, subject characteristics, and other factors that may limit direct comparability.

Future Outlook

Neumora Therapeutics anticipates a catalyst-rich period in 2026 with multiple clinical data readouts. The company plans to advance NMRA-511 into higher dose studies and develop a once-daily formulation, initiate a Phase 2/3 study, and expects joint topline data for navacaprant's KOASTAL-2 and -3 studies in Q2 2026. A clinical program for NMRA-215 in obesity is slated for H1 2026 with weight loss data expected by year-end, and an M4 franchise update is planned for mid-2026. The company's financial position is strong, with cash expected to support operations into Q3 2027.

Management Comments

• "We are encouraged by these data, which demonstrate a clear clinical effect that NMRA-511 meaningfully improves agitation symptoms among people with AD agitation, and has an unsurpassed effect size among patients with higher levels of baseline anxiety, with a favorable safety and tolerability profile." Bill Aurora, Pharm.D., Chief Operating and Development Officer, Neumora.
• "Anxiety is often an underlying symptom that is present early in the AD agitation disease course, and there is an unmet need for tolerable therapies that can reduce agitation and anxiety symptoms. We look forward to advancing the program and exploring higher doses of NMRA-511." Bill Aurora, Pharm.D., Chief Operating and Development Officer, Neumora.
• "2025 was a productive and strategically important year for Neumora, as we advanced our pipeline of novel mechanism therapies, prioritized obesity as the lead indication for our highly brain-penetrant NLRP3 inhibitor, NMRA-215, expanded our M4 PAM franchise with two new programs in clinical development, progressed the Phase 3 program for navacaprant, and produced compelling data for NMRA-511 – all while continuing to strengthen our financial foundation." Paul L. Berns, Co-founder, Chairman and Chief Executive Officer, Neumora.
• "This progress set up important expected milestones across our programs. We are entering a catalyst-rich period that I believe will meaningfully shape the future of Neumora, as well as the future of treatment for several underserved disease areas." Paul L. Berns, Co-founder, Chairman and Chief Executive Officer, Neumora.

Industry Context

The positive results for NMRA-511 in Alzheimer's disease agitation address a significant unmet medical need, as existing treatments are often limited by modest efficacy and tolerability concerns. The focus on the vasopressin 1a receptor (V1aR) represents a novel mechanism of action in a field where innovation is highly sought after. The expansion into obesity with NMRA-215, following promising preclinical data, positions Neumora in a rapidly growing and competitive market for weight management therapies. The continued advancement of the M4 PAM franchise and navacaprant for MDD further diversifies the company's neuroscience pipeline, aligning with broader industry trends towards precision medicine and novel targets for complex brain diseases.

Comparison to Industry Standards

• NMRA-511 demonstrated an "unsurpassed clinical effect size" on CMAI total score in the pre-specified population with elevated anxiety, suggesting a potentially superior efficacy profile compared to existing or developing treatments for AD agitation, though direct comparisons to specific competitor compounds or studies are not provided in the filing.
• The favorable tolerability and safety profile of NMRA-511, with no reports of somnolence or sedation and low discontinuation rates (2.5%), is a significant advantage given that existing AD agitation treatments are often limited by tolerability and safety concerns.
• NMRA-215 is described as having "class-leading preclinical data" for obesity, implying a strong competitive position against other NLRP3 inhibitors or emerging obesity treatments in early development, though specific comparative data points are not detailed.

Stakeholder Impact

• Shareholders/Investors: Positive clinical data and pipeline progress could increase investor confidence and potentially lead to share price appreciation. The extended cash runway reduces immediate dilution risk.
• Patients with AD Agitation: NMRA-511 offers a promising new therapeutic option with a favorable safety profile, potentially improving quality of life and reducing the burden of agitation symptoms.
• Caregivers of AD Patients: A more effective and tolerable treatment for agitation could significantly alleviate caregiver stress and improve patient management.
• Employees: Continued pipeline success and financial stability provide job security and potential for growth within the company.
• Healthcare Providers: New treatment options for AD agitation and other neurological disorders could enhance treatment paradigms and patient outcomes.

Next Steps

• Initiate a multiple ascending dose extension study investigating higher doses of NMRA-511 in 2026.
• Conduct formulation development to enable once-daily dosing via an extended-release formulation of NMRA-511 in 2026.
• Initiate a Phase 2/3 dose ranging study with NMRA-511.
• Joint topline data readout for KOASTAL-2 and KOASTAL-3 (navacaprant for MDD) in Q2 2026.
• Initiate a clinical program evaluating NMRA-215 monotherapy and combination therapy for obesity in H1 2026.
• Report weight loss data following treatment with NMRA-215 around the end of 2026.
• Provide a comprehensive M4 franchise update in mid-2026, including potentially advancing development of one or both programs (NMRA-898 and NMRA-861).

Key Dates

Recommendation

The positive Phase 1b results for NMRA-511 in AD agitation, demonstrating both clinically meaningful efficacy and an unsurpassed effect size in a key sub-population with a favorable safety profile, significantly de-risk a major pipeline asset. This, coupled with a robust pipeline of other programs advancing towards multiple significant data readouts in 2026 (navacaprant, NMRA-215, M4 PAMs) and a strong cash position extending into Q3 2027, indicates substantial near-term catalysts and long-term value creation potential. The company is well-funded to execute on its strategic goals, making it an attractive investment opportunity.

Keywords

Neumora Therapeutics, NMRA, Alzheimer's Disease Agitation, NMRA-511, Vasopressin 1a Receptor Antagonist, V1aR, Neuroscience, Clinical Trials, Phase 1b, Drug Development, Pipeline Updates, Navacaprant, Major Depressive Disorder, MDD, KOASTAL, NMRA-215, Obesity, NLRP3 Inhibitor, M4 PAM, Biopharmaceutical, Clinical-stage, Brain Diseases